Big pharma, Financing

Valeant Pharmaceuticals raises $1 billion in private financing

Posted on 15 January 2015

Tags: , ,

Big pharma, Valeant Pharmaceuticals International, has completed the private placement financing of senior unsecured notes due 2023, for gross proceeds of USD1 billion.

The notes bear an interest rate of 5.5% per annum and will mature on March 1, 2023.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

Interest on the notes will be payable semi-annually in arrears on each March 1 and September 1.

Interest on the notes will accrue from January 30, 2015.

The notes guaranteed by each of Valeant Pharma’s subsidiaries that is a guarantor of the Valeant Pharma's senior secured credit facilities.

The offering was subscribed to by qualified institutional investors.

The company intends to use the proceeds from the financing  to finance the redemption of all of the outstanding 6.875% senior notes due 2018; to repay all or a portion of the amounts drawn under its revolving credit facility, and for general corporate purposes, including acquisitions.

For further financing deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply